Controlling Rapid Atrial Fibrillation With Dexmedetomidine — C-RAD  

Heart Rate Control Clinical Trial

Official title: Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial

Status Terminated

Clinical Trial Summary

The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.

Clinical Trial Description

Dexmedetomidine is a commonly used sedative/anxiolytic agent in the ICU with sympatholytic properties that can cause a decrease in heart rate. Eligible patients will be randomized into one of two groups: SOC plus Dex arm or SOC plus placebo (normal saline) arm. Study drug infusion will be administered at an infusion rate of 1μg/kg/hr via IV, and will not include a loading dose. Four 6-second telemetry rhythm strips will be collected per hour, starting one hour prior to study drug infusion, during the eight hour infusion period, and two hours post infusion cessation). Degree of heart rate control and time to heart rate control for both groups will be analyzed. ;

Related Conditions & MeSH terms

• Atrial Fibrillation
• Heart Rate Control
• Rapid Atrial Fibrillation

• NCT number: NCT04042727
• Study type: Interventional
• Source: Stony Brook University
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: August 21, 2019
• Completion date: December 31, 2021